{"id":11325,"date":"2017-11-30T23:00:00","date_gmt":"2017-11-30T22:00:00","guid":{"rendered":"https:\/\/lombardialifesciences.it\/lancio-imi2-call-13\/"},"modified":"2023-06-22T22:16:16","modified_gmt":"2023-06-22T20:16:16","slug":"lancio-imi2-call-13","status":"publish","type":"post","link":"https:\/\/lombardialifesciences.it\/en\/lancio-imi2-call-13\/","title":{"rendered":"Lancio IMI2 Call 13"},"content":{"rendered":"<p><p>La Innovative Medicine Initiative ha lanciato la <strong>IMI2 Call 13<\/strong>.<\/p>\n<p>I topic sono i seguenti:<\/p>\n<ul>\n<li>Assessment of the uniqueness of <strong>diabetic cardiomyopathy<\/strong> relative to other forms of heart failure using unbiased pheno-mapping approaches<\/li>\n<li>Genome-environment interactions in <strong>inflammatory skin disease<\/strong><\/li>\n<li>The value of diagnostics to combat <strong>antimicrobial resistance<\/strong> by optimising antibiotic use<\/li>\n<li><strong>Mitochondrial dysfunction in neurodegeneration<\/strong><\/li>\n<li>Support and coordination action for the projects of the <strong>neurodegeneration<\/strong> area of the Innovative Medicines Initiative<\/li>\n<li>A sustainable European induced pluripotent <strong>stem cell platform<\/strong><\/li>\n<li>Linking digital assessment of mobility to clinical endpoints to drive <strong>regulatory acceptance and clinical practice<\/strong><\/li>\n<li><strong>Human tumour microenvironment immunoprofiling<\/strong><\/li>\n<li>CONCEPTION \u2013 continuum of evidence from <strong>pregnancy exposures, reproductive toxicology and breastfeeding<\/strong> to improve outcomes now<\/li>\n<li>Improving the preclinical prediction of adverse effects of <strong>pharmaceuticals on the nervous system<\/strong><\/li>\n<li>Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety <strong>biomarkers in clinical trials and diagnosis of disease<\/strong><\/li>\n<li>Pilot programme on a <strong>clinical compound bank for repurposing<\/strong> (This programme includes the following topics: cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; rare\/orphan diseases)<\/li>\n<\/ul>\n<hr>\n<p>A seguito di una discussione in proposito tra IMI Office, EFPIA e EC, il topic &#8220;Development of a Platform for Federated and Privacy-Preserving Machine Learning in Support of Drug Discovery&#8221; \u00e8 stato ritirato dalla Call 13. Tuttavia, esso sar\u00e0 preso in considerazione per future call.<\/p>\n<hr>\n<p><strong>La deadline per inviare le proposte \u00e8 il 28 Febbraio 2018. <\/strong><\/p>\n<p><a href=\"http:\/\/www.imi.europa.eu\/apply-funding\/open-calls\/imi2-call-13\">Clicca qui<\/a> per il testo orginale.<\/p>\n<hr>\n<p>Inoltre, dallo scorso luned\u00ec 27 novembre, \u00e8 iniziata la serie di Webinar specifici sui vari Topic della Call 13. E&#8217; ancora possibile registrarsi alla maggior parte di essi visitando la <a href=\"http:\/\/www.imi.europa.eu\/news-events\/events\/webinars-imi2-call-13\">pagina ufficiale<\/a>.<\/p>\n<p>La registrazione \u00e8 gratuita ma obbligatoria.<\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Innovative Medicine Initiative ha lanciato la IMI2 Call 13. I topic sono i seguenti: Assessment o&#8230;<\/p>\n","protected":false},"author":1,"featured_media":11326,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[44],"tags":[],"class_list":["post-11325","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/posts\/11325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/comments?post=11325"}],"version-history":[{"count":1,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/posts\/11325\/revisions"}],"predecessor-version":[{"id":16675,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/posts\/11325\/revisions\/16675"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/media\/11326"}],"wp:attachment":[{"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/media?parent=11325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/categories?post=11325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lombardialifesciences.it\/en\/wp-json\/wp\/v2\/tags?post=11325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}